{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:34:42Z","timestamp":1792802082183,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Eduardo Chini","award":["NIH (grant AR074523)"],"award-info":[{"award-number":["NIH (grant AR074523)"]}]},{"name":"John Varga","award":["NIH (grant AR074523)"],"award-info":[{"award-number":["NIH (grant AR074523)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The functionally pleiotropic ectoenzyme CD38 is a glycohydrolase widely expressed on immune and non-hematopoietic cells. By converting NAD<jats:sup>+<\/jats:sup> to ADP-ribose and nicotinamide, CD38 governs organismal NAD<jats:sup>+<\/jats:sup> homeostasis and the activity of NAD<jats:sup>+<\/jats:sup>-dependent cellular enzymes. CD38 has emerged as a major driver of age-related NAD<jats:sup>+<\/jats:sup> decline underlying adverse metabolic states, frailty and reduced health span. CD38 is upregulated in systemic sclerosis (SSc), a chronic disease characterized by fibrosis in multiple organs. We sought to test the hypothesis that inhibition of the CD38 ecto-enzymatic activity using a heavy-chain monoclonal antibody Ab68 will, via augmenting organismal NAD<jats:sup>+<\/jats:sup>, prevent fibrosis in a mouse model of SSc characterized by NAD<jats:sup>+<\/jats:sup> depletion. Here we show that treatment of mice with a non-cytotoxic heavy-chain antibody that selectively inhibits CD38 ectoenzyme resulted in NAD<jats:sup>+<\/jats:sup> boosting that was associated with significant protection from fibrosis in multiple organs. These findings suggest that targeted inhibition of CD38 ecto-enzymatic activity could be a potential pharmacological approach for SSc fibrosis\u00a0treatment.<\/jats:p>","DOI":"10.1038\/s41598-023-49450-1","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T20:02:21Z","timestamp":1702411341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Heavy-chain antibody targeting of CD38 NAD+ hydrolase ectoenzyme to prevent fibrosis in multiple organs"],"prefix":"10.1038","volume":"13","author":[{"given":"Bo","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranjali","family":"Dalvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lukacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cheresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais R.","family":"Peclat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia C.","family":"Chini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo N.","family":"Chini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van Schooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"49450_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.semcdb.2019.12.007","volume":"101","author":"Y Asano","year":"2019","unstructured":"Asano, Y. & Varga, J. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies. Semin. Cell Dev. Biol. 101, 148\u2013160. https:\/\/doi.org\/10.1016\/j.semcdb.2019.12.007 (2019).","journal-title":"Semin. Cell Dev. Biol."},{"key":"49450_CR2","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore, Y. et al. Systemic sclerosis. Nat. Rev. Dis. Prim. 1, 15002. https:\/\/doi.org\/10.1038\/nrdp.2015.2 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"49450_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga, J. & Abraham, D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J. Clin. Invest. 117, 557\u2013567. https:\/\/doi.org\/10.1172\/JCI31139 (2007).","journal-title":"J. Clin. Invest."},{"key":"49450_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","volume":"15","author":"JHW Distler","year":"2019","unstructured":"Distler, J. H. W. et al. Shared and distinct mechanisms of fibrosis. Nat. Rev. Rheumatol. 15, 705\u2013730. https:\/\/doi.org\/10.1038\/s41584-019-0322-7 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"49450_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","volume":"8","author":"S Bhattacharyya","year":"2011","unstructured":"Bhattacharyya, S., Wei, J. & Varga, J. Understanding fibrosis in systemic sclerosis: Shifting paradigms, emerging opportunities. Nat. Rev. Rheumatol. 8, 42\u201354. https:\/\/doi.org\/10.1038\/nrrheum.2011.149 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"49450_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nrrheum.2014.53","volume":"10","author":"YY Ho","year":"2014","unstructured":"Ho, Y. Y., Lagares, D., Tager, A. M. & Kapoor, M. Fibrosis\u2013a lethal component of systemic sclerosis. Nat. Rev. Rheumatol. 10, 390\u2013402. https:\/\/doi.org\/10.1038\/nrrheum.2014.53 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"49450_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41584-019-0184-z","volume":"15","author":"ER Volkmann","year":"2019","unstructured":"Volkmann, E. R. & Varga, J. Emerging targets of disease-modifying therapy for systemic sclerosis. Nat. Rev. Rheumatol. 15, 208\u2013224. https:\/\/doi.org\/10.1038\/s41584-019-0184-z (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"49450_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41584-019-0324-5","volume":"16","author":"B Hinz","year":"2020","unstructured":"Hinz, B. & Lagares, D. Evasion of apoptosis by myofibroblasts: A hallmark of fibrotic diseases. Nat. Rev. Rheumatol. 16, 11\u201331. https:\/\/doi.org\/10.1038\/s41584-019-0324-5 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"49450_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.cmet.2017.11.002","volume":"27","author":"J Yoshino","year":"2018","unstructured":"Yoshino, J., Baur, J. A. & Imai, S. I. NAD(+) intermediates: The biology and therapeutic potential of NMN and NR. Cell Metab. 27, 513\u2013528. https:\/\/doi.org\/10.1016\/j.cmet.2017.11.002 (2018).","journal-title":"Cell Metab."},{"key":"49450_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.mce.2016.11.003","volume":"455","author":"CCS Chini","year":"2017","unstructured":"Chini, C. C. S., Tarrago, M. G. & Chini, E. N. NAD and the aging process: Role in life, death and everything in between. Mol. Cell Endocrinol. 455, 62\u201374. https:\/\/doi.org\/10.1016\/j.mce.2016.11.003 (2017).","journal-title":"Mol. Cell Endocrinol."},{"key":"49450_CR11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cmet.2016.05.006","volume":"23","author":"J Camacho-Pereira","year":"2016","unstructured":"Camacho-Pereira, J. et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 23, 1127\u20131139. https:\/\/doi.org\/10.1016\/j.cmet.2016.05.006 (2016).","journal-title":"Cell Metab."},{"key":"49450_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.cmet.2016.07.005","volume":"24","author":"DW Frederick","year":"2016","unstructured":"Frederick, D. W. et al. Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscle. Cell Metab. 24, 269\u2013282. https:\/\/doi.org\/10.1016\/j.cmet.2016.07.005 (2016).","journal-title":"Cell Metab."},{"key":"49450_CR13","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.cell.2013.11.037","volume":"155","author":"AP Gomes","year":"2013","unstructured":"Gomes, A. P. et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155, 1624\u20131638. https:\/\/doi.org\/10.1016\/j.cell.2013.11.037 (2013).","journal-title":"Cell"},{"key":"49450_CR14","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1073\/pnas.1417921112","volume":"112","author":"XH Zhu","year":"2015","unstructured":"Zhu, X. H., Lu, M., Lee, B. Y., Ugurbil, K. & Chen, W. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc. National Acad. Sci. U. S. A. 112, 2876\u20132881. https:\/\/doi.org\/10.1073\/pnas.1417921112 (2015).","journal-title":"Proc. National Acad. Sci. U. S. A."},{"key":"49450_CR15","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cmet.2018.03.016","volume":"27","author":"MG Tarrago","year":"2018","unstructured":"Tarrago, M. G. et al. A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD(+) decline. Cell Metab. 27, 1081\u20131095. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.016 (2018).","journal-title":"Cell Metab."},{"key":"49450_CR16","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1535370220929287","volume":"245","author":"JW Kincaid","year":"2020","unstructured":"Kincaid, J. W. & Berger, N. A. NAD metabolism in aging and cancer. Exp. Biol. Med. (Maywood) 245, 1594\u20131614. https:\/\/doi.org\/10.1177\/1535370220929287 (2020).","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"49450_CR17","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.bbrc.2006.05.042","volume":"345","author":"P Aksoy","year":"2006","unstructured":"Aksoy, P., White, T. A., Thompson, M. & Chini, E. N. Regulation of intracellular levels of NAD: A novel role for CD38. Biochem. Biophys. Res. Commun. 345, 1386\u20131392. https:\/\/doi.org\/10.1016\/j.bbrc.2006.05.042 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"49450_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.bbrc.2006.08.066","volume":"349","author":"P Aksoy","year":"2006","unstructured":"Aksoy, P. et al. Regulation of SIRT 1 mediated NAD dependent deacetylation: A novel role for the multifunctional enzyme CD38. Biochem. Biophys. Res. Commun. 349, 353\u2013359. https:\/\/doi.org\/10.1016\/j.bbrc.2006.08.066 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"49450_CR19","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1096\/fj.07-8290com","volume":"21","author":"MT Barbosa","year":"2007","unstructured":"Barbosa, M. T. et al. The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity. FASEB J. 21, 3629\u20133639. https:\/\/doi.org\/10.1096\/fj.07-8290com (2007).","journal-title":"FASEB J."},{"key":"49450_CR20","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cmet.2021.04.003","volume":"33","author":"CCS Chini","year":"2021","unstructured":"Chini, C. C. S., Zeidler, J. D., Kashyap, S., Warner, G. & Chini, E. N. Evolving concepts in NAD(+) metabolism. Cell Metab 33, 1076\u20131087. https:\/\/doi.org\/10.1016\/j.cmet.2021.04.003 (2021).","journal-title":"Cell Metab"},{"key":"49450_CR21","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","volume":"10","author":"KA Hogan","year":"2019","unstructured":"Hogan, K. A., Chini, C. C. S. & Chini, E. N. The multi-faceted ecto-enzyme CD38: Roles in immunomodulation, cancer, aging, and metabolic diseases. Front. Immunol. 10, 1187. https:\/\/doi.org\/10.3389\/fimmu.2019.01187 (2019).","journal-title":"Front. Immunol."},{"key":"49450_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.tips.2018.02.001","volume":"39","author":"EN Chini","year":"2018","unstructured":"Chini, E. N., Chini, C. C. S., Espindola Netto, J. M., de Oliveira, G. C. & van Schooten, W. The pharmacology of CD38\/NADase: An emerging target in cancer and diseases of aging. Trends Pharmacol. Sci. 39, 424\u2013436. https:\/\/doi.org\/10.1016\/j.tips.2018.02.001 (2018).","journal-title":"Trends Pharmacol. Sci."},{"key":"49450_CR23","doi-asserted-by":"publisher","first-page":"1072462","DOI":"10.3389\/fimmu.2022.1072462","volume":"13","author":"S Agarbati","year":"2022","unstructured":"Agarbati, S. et al. Increased expression of the ectoenzyme CD38 in peripheral blood plasmablasts and plasma cells of patients with systemic sclerosis. Front. Immunol. 13, 1072462. https:\/\/doi.org\/10.3389\/fimmu.2022.1072462 (2022).","journal-title":"Front. Immunol."},{"key":"49450_CR24","doi-asserted-by":"publisher","first-page":"101902","DOI":"10.1016\/j.isci.2020.101902","volume":"24","author":"B Shi","year":"2021","unstructured":"Shi, B. et al. Targeting CD38-dependent NAD(+) metabolism to mitigate multiple organ fibrosis. iScience 24, 101902. https:\/\/doi.org\/10.1016\/j.isci.2020.101902 (2021).","journal-title":"iScience"},{"key":"49450_CR25","doi-asserted-by":"publisher","first-page":"2095949","DOI":"10.1080\/19420862.2022.2095949","volume":"14","author":"HS Ugamraj","year":"2022","unstructured":"Ugamraj, H. S. et al. TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity. MAbs 14, 2095949. https:\/\/doi.org\/10.1080\/19420862.2022.2095949 (2022).","journal-title":"MAbs"},{"key":"49450_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41556-019-0287-4","volume":"21","author":"T Nacarelli","year":"2019","unstructured":"Nacarelli, T. et al. NAD(+) metabolism governs the proinflammatory senescence-associated secretome. Nat. Cell Biol. 21, 397\u2013407. https:\/\/doi.org\/10.1038\/s41556-019-0287-4 (2019).","journal-title":"Nat. Cell Biol."},{"key":"49450_CR27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.bbrc.2019.03.199","volume":"513","author":"C Chini","year":"2019","unstructured":"Chini, C. et al. The NADase CD38 is induced by factors secreted from senescent cells providing a potential link between senescence and age-related cellular NAD(+) decline. Biochem. Biophys. Res. Commun. 513, 486\u2013493. https:\/\/doi.org\/10.1016\/j.bbrc.2019.03.199 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"49450_CR28","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/art.39061","volume":"67","author":"J Wei","year":"2015","unstructured":"Wei, J. et al. The histone deacetylase sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor beta signaling. Arthritis Rheumatol. 67, 1323\u20131334. https:\/\/doi.org\/10.1002\/art.39061 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"49450_CR29","doi-asserted-by":"publisher","first-page":"69321","DOI":"10.18632\/oncotarget.12504","volume":"7","author":"K Akamata","year":"2016","unstructured":"Akamata, K. et al. SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis. Oncotarget 7, 69321\u201369336. https:\/\/doi.org\/10.18632\/oncotarget.12504 (2016).","journal-title":"Oncotarget"},{"key":"49450_CR30","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1152\/physrev.00035.2007","volume":"88","author":"F Malavasi","year":"2008","unstructured":"Malavasi, F. et al. Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology. Physiol. Rev. 88, 841\u2013886. https:\/\/doi.org\/10.1152\/physrev.00035.2007 (2008).","journal-title":"Physiol. Rev."},{"key":"49450_CR31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/BOR.0000000000000737","volume":"32","author":"TR Peclat","year":"2020","unstructured":"Peclat, T. R., Shi, B., Varga, J. & Chini, E. N. The NADase enzyme CD38: An emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Curr. Opin. Rheumatol. 32, 488\u2013496. https:\/\/doi.org\/10.1097\/BOR.0000000000000737 (2020).","journal-title":"Curr. Opin. Rheumatol."},{"key":"49450_CR32","doi-asserted-by":"publisher","first-page":"C521","DOI":"10.1152\/ajpcell.00451.2021","volume":"322","author":"JD Zeidler","year":"2022","unstructured":"Zeidler, J. D. et al. The CD38 glycohydrolase and the NAD sink: Implications for pathological conditions. Am. J. Physiol. Cell Physiol. 322, C521\u2013C545. https:\/\/doi.org\/10.1152\/ajpcell.00451.2021 (2022).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"49450_CR33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1164\/rccm.202109-2151OC","volume":"206","author":"HC Cui","year":"2022","unstructured":"Cui, H. C. et al. CD38 mediates lung fibrosis by promoting alveolar epithelial cell aging. Am. J. Resp. Crit. Care 206, 459\u2013475. https:\/\/doi.org\/10.1164\/rccm.202109-2151OC (2022).","journal-title":"Am. J. Resp. Crit. Care"},{"key":"49450_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020471","author":"S Guerreiro","year":"2020","unstructured":"Guerreiro, S., Privat, A. L., Bressac, L. & Toulorge, D. CD38 in neurodegeneration and neuroinflammation. Cells https:\/\/doi.org\/10.3390\/cells9020471 (2020).","journal-title":"Cells"},{"key":"49450_CR35","doi-asserted-by":"publisher","first-page":"25938","DOI":"10.1074\/jbc.M113.470435","volume":"288","author":"A Grozio","year":"2013","unstructured":"Grozio, A. et al. CD73 protein as a source of extracellular precursors for sustained NAD(+) biosynthesis in FK866-treated tumor cells. J. Biol. Chem. 288, 25938\u201325949. https:\/\/doi.org\/10.1074\/jbc.M113.470435 (2013).","journal-title":"J. Biol. Chem."},{"key":"49450_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-00298-z","author":"CCS Chini","year":"2020","unstructured":"Chini, C. C. S. et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD(+) and NMN levels. Nat. Metab https:\/\/doi.org\/10.1038\/s42255-020-00298-z (2020).","journal-title":"Nat. Metab"},{"key":"49450_CR37","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nrm.2016.93","volume":"17","author":"MS Bonkowski","year":"2016","unstructured":"Bonkowski, M. S. & Sinclair, D. A. Slowing ageing by design: The rise of NAD(+) and sirtuin-activating compounds. Nat. Rev. Mol. Cell Biol. 17, 679\u2013690. https:\/\/doi.org\/10.1038\/nrm.2016.93 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"49450_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0724-6","author":"AE Wyman","year":"2018","unstructured":"Wyman, A. E. & Atamas, S. P. Sirtuins and accelerated aging in scleroderma. Curr. Rheumatol. Rep. https:\/\/doi.org\/10.1007\/s11926-018-0724-6 (2018).","journal-title":"Curr. Rheumatol. Rep."},{"key":"49450_CR39","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.celrep.2013.03.019","volume":"3","author":"P Simic","year":"2013","unstructured":"Simic, P. et al. SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep. 3, 1175\u20131186. https:\/\/doi.org\/10.1016\/j.celrep.2013.03.019 (2013).","journal-title":"Cell Rep."},{"key":"49450_CR40","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/gerona\/glw151","volume":"72","author":"ML Sosulski","year":"2017","unstructured":"Sosulski, M. L., Gongora, R., Feghali-Bostwick, C., Lasky, J. A. & Sanchez, C. G. Sirtuin 3 deregulation promotes pulmonary fibrosis. J. Gerontol. A Biol. Sci. Med. Sci. 72, 595\u2013602. https:\/\/doi.org\/10.1093\/gerona\/glw151 (2017).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"49450_CR41","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1096\/fj.201601077R","volume":"31","author":"RP Jablonski","year":"2017","unstructured":"Jablonski, R. P. et al. SIRT3 deficiency promotes lung fibrosis by augmenting alveolar epithelial cell mitochondrial DNA damage and apoptosis. Faseb J. 31, 2520\u20132532. https:\/\/doi.org\/10.1096\/fj.201601077R (2017).","journal-title":"Faseb J."},{"key":"49450_CR42","doi-asserted-by":"publisher","first-page":"107983","DOI":"10.1016\/j.pharmthera.2021.107983","volume":"229","author":"X Han","year":"2022","unstructured":"Han, X. et al. Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy. Pharmacol. Ther. 229, 107983. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107983 (2022).","journal-title":"Pharmacol. Ther."},{"key":"49450_CR43","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1210\/en.2003-0774","volume":"145","author":"H Barata","year":"2004","unstructured":"Barata, H. et al. The role of cyclic-ADP-ribose-signaling pathway in oxytocin-induced Ca2+ transients in human myometrium cells. Endocrinology 145, 881\u2013889. https:\/\/doi.org\/10.1210\/en.2003-0774 (2004).","journal-title":"Endocrinology"},{"key":"49450_CR44","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10059-012-0263-3","volume":"34","author":"CU Lee","year":"2012","unstructured":"Lee, C. U., Song, E. K., Yoo, C. H., Kwak, Y. K. & Han, M. K. Lipopolysaccharide induces CD38 expression and solubilization in J774 macrophage cells. Mol. Cells 34, 573\u2013576. https:\/\/doi.org\/10.1007\/s10059-012-0263-3 (2012).","journal-title":"Mol. Cells"},{"key":"49450_CR45","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1189\/jlb.69.4.605","volume":"69","author":"T Musso","year":"2001","unstructured":"Musso, T. et al. CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines. J. Leukoc. Biol. 69, 605\u2013612 (2001).","journal-title":"J. Leukoc. Biol."},{"key":"49450_CR46","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3389\/fimmu.2018.01593","volume":"9","author":"SA Amici","year":"2018","unstructured":"Amici, S. A. et al. CD38 is robustly induced in human macrophages and monocytes in inflammatory conditions. Front. Immunol. 9, 1593. https:\/\/doi.org\/10.3389\/fimmu.2018.01593 (2018).","journal-title":"Front. Immunol."},{"issue":"Suppl 1","key":"49450_CR47","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1093\/gerona\/glu057","volume":"69","author":"C Franceschi","year":"2014","unstructured":"Franceschi, C. & Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A Biol. Sci. Med. Sci. 69(Suppl 1), S4-9. https:\/\/doi.org\/10.1093\/gerona\/glu057 (2014).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"49450_CR48","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ncb1909","volume":"11","author":"F Rodier","year":"2009","unstructured":"Rodier, F. et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 11, 973\u2013979. https:\/\/doi.org\/10.1038\/ncb1909 (2009).","journal-title":"Nat. Cell Biol."},{"key":"49450_CR49","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/s42255-020-00305-3","volume":"2","author":"AJ Covarrubias","year":"2020","unstructured":"Covarrubias, A. J. et al. Senescent cells promote tissue NAD(+) decline during ageing via the activation of CD38(+) macrophages. Nat. Metab. 2, 1265\u20131283. https:\/\/doi.org\/10.1038\/s42255-020-00305-3 (2020).","journal-title":"Nat. Metab."},{"key":"49450_CR50","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cmet.2015.11.011","volume":"23","author":"CD Wiley","year":"2016","unstructured":"Wiley, C. D. et al. Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. Cell Metab. 23, 303\u2013314. https:\/\/doi.org\/10.1016\/j.cmet.2015.11.011 (2016).","journal-title":"Cell Metab."},{"key":"49450_CR51","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/s0008-8749(03)00025-x","volume":"220","author":"R Lande","year":"2002","unstructured":"Lande, R. et al. CD38 ligation plays a direct role in the induction of IL-1beta, IL-6, and IL-10 secretion in resting human monocytes. Cell Immunol. 220, 30\u201338. https:\/\/doi.org\/10.1016\/s0008-8749(03)00025-x (2002).","journal-title":"Cell Immunol."},{"key":"49450_CR52","doi-asserted-by":"publisher","first-page":"597959","DOI":"10.3389\/fimmu.2020.597959","volume":"11","author":"ZL Piedra-Quintero","year":"2020","unstructured":"Piedra-Quintero, Z. L., Wilson, Z., Nava, P. & Guerau-de-Arellano, M. CD38: An immunomodulatory molecule in inflammation and autoimmunity. Front. Immunol. 11, 597959. https:\/\/doi.org\/10.3389\/fimmu.2020.597959 (2020).","journal-title":"Front. Immunol."},{"key":"49450_CR53","doi-asserted-by":"publisher","first-page":"e2211310119","DOI":"10.1073\/pnas.2211310119","volume":"119","author":"T Meyer","year":"2022","unstructured":"Meyer, T. et al. NAD(+) metabolism drives astrocyte proinflammatory reprogramming in central nervous system autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 119, e2211310119. https:\/\/doi.org\/10.1073\/pnas.2211310119 (2022).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"49450_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/art.42351","author":"P Gil Alabarse","year":"2022","unstructured":"Gil Alabarse, P., Chen, L. Y., Oliveira, P., Qin, H. & Liu-Bryan, R. Targeting CD38 to suppress osteoarthritis development and associated pain after joint injury in mice. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.42351 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"49450_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.09.652","author":"B Shi","year":"2022","unstructured":"Shi, B. et al. Senescent cells accumulate in systemic sclerosis skin. J Invest. Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2022.09.652 (2022).","journal-title":"J Invest. Dermatol."},{"key":"49450_CR56","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","volume":"160","author":"S Deaglio","year":"1998","unstructured":"Deaglio, S. et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J. Immunol. 160, 395\u2013402 (1998).","journal-title":"J. Immunol."},{"key":"49450_CR57","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1128\/IAI.00340-13","volume":"81","author":"T Lischke","year":"2013","unstructured":"Lischke, T. et al. CD38 controls the innate immune response against Listeria monocytogenes. Infect. Immunol. 81, 4091\u20134099. https:\/\/doi.org\/10.1128\/IAI.00340-13 (2013).","journal-title":"Infect. Immunol."},{"key":"49450_CR58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1286-4579(02)00055-2","volume":"5","author":"S Partida-Sanchez","year":"2003","unstructured":"Partida-Sanchez, S., Randall, T. D. & Lund, F. E. Innate immunity is regulated by CD38, an ecto-enzyme with ADP-ribosyl cyclase activity. Microbes Infect. 5, 49\u201358. https:\/\/doi.org\/10.1016\/S1286-4579(02)00055-2 (2003).","journal-title":"Microbes Infect."},{"key":"49450_CR59","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm1101-1209","volume":"7","author":"S Partida-Sanchez","year":"2001","unstructured":"Partida-Sanchez, S. et al. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat. Med. 7, 1209\u20131216. https:\/\/doi.org\/10.1038\/nm1101-1209 (2001).","journal-title":"Nat. Med."},{"key":"49450_CR60","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s10165-009-0251-4","volume":"20","author":"ES Chan","year":"2010","unstructured":"Chan, E. S. & Cronstein, B. N. Adenosine in fibrosis. Mod. Rheumatol. 20, 114\u2013122. https:\/\/doi.org\/10.1007\/s10165-009-0251-4 (2010).","journal-title":"Mod. Rheumatol."},{"key":"49450_CR61","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/art.41259","volume":"72","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Recombinant adenosine deaminase ameliorates inflammation, vascular disease, and fibrosis in preclinical models of systemic sclerosis. Arthritis Rheumatol. 72, 1385\u20131395. https:\/\/doi.org\/10.1002\/art.41259 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"49450_CR62","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.neuron.2007.04.011","volume":"54","author":"LJ Young","year":"2007","unstructured":"Young, L. J. Regulating the social brain: A new role for CD38. Neuron 54, 353\u2013356. https:\/\/doi.org\/10.1016\/j.neuron.2007.04.011 (2007).","journal-title":"Neuron"},{"key":"49450_CR63","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuint.2017.07.009","volume":"119","author":"H Higashida","year":"2018","unstructured":"Higashida, H. et al. Oxytocin release via activation of TRPM2 and CD38 in the hypothalamus during hyperthermia in mice: Implication for autism spectrum disorder. Neurochem. Int. 119, 42\u201348. https:\/\/doi.org\/10.1016\/j.neuint.2017.07.009 (2018).","journal-title":"Neurochem. Int."},{"key":"49450_CR64","doi-asserted-by":"publisher","first-page":"e98850","DOI":"10.1172\/jci.insight.98850","volume":"3","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya, S. et al. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. JCI Insight 3, e98850. https:\/\/doi.org\/10.1172\/jci.insight.98850 (2018).","journal-title":"JCI Insight"},{"key":"49450_CR65","doi-asserted-by":"publisher","first-page":"11703","DOI":"10.1038\/ncomms11703","volume":"7","author":"S Bhattacharyya","year":"2016","unstructured":"Bhattacharyya, S. et al. Tenascin-C drives persistence of organ fibrosis. Nat. Commun. 7, 11703. https:\/\/doi.org\/10.1038\/ncomms11703 (2016).","journal-title":"Nat. Commun."},{"key":"49450_CR66","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jcp.41.4.467","volume":"41","author":"T Ashcroft","year":"1988","unstructured":"Ashcroft, T., Simpson, J. M. & Timbrell, V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 41, 467\u2013470. https:\/\/doi.org\/10.1136\/jcp.41.4.467 (1988).","journal-title":"J. Clin. Pathol."},{"key":"49450_CR67","doi-asserted-by":"publisher","first-page":"E10605","DOI":"10.1073\/pnas.1807067115","volume":"115","author":"SM Hrycaj","year":"2018","unstructured":"Hrycaj, S. M. et al. Hox5 genes direct elastin network formation during alveologenesis by regulating myofibroblast adhesion. Proc. Natl. Acad. Sci. U. S. A. 115, E10605\u2013E10614. https:\/\/doi.org\/10.1073\/pnas.1807067115 (2018).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"49450_CR68","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.3389\/fimmu.2018.02434","volume":"9","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya, S. et al. Pharmacological inhibition of toll-like receptor-4 signaling by TAK242 prevents and induces regression of experimental organ fibrosis. Front. Immunol. 9, 2434. https:\/\/doi.org\/10.3389\/fimmu.2018.02434 (2018).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49450-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49450-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49450-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T20:05:06Z","timestamp":1702411506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49450-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["49450"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-49450-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"21 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"John Varga- Receives consulting fees from, and owns equity shares in TeneoFour. Eduaurdo N. Chini- Receives consulting fees and owns equity shares in TeneoFour.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22085"}}